European registration: today, tomorrow, and beyond

Area of Science:

• Pharmaceutical regulatory affairs
• European Union drug policy
• Drug registration processes

Background:

• National pharmaceutical regulatory systems within European Community (EC) countries exhibit variable efficiency and scientific sophistication.
• The overarching objective of mutual recognition for drug approvals at the EC level has not been successfully implemented.
• Achieving simultaneous marketing approvals across member states requires significant revisions to existing regulatory procedures.

Purpose of the Study:

• To analyze the challenges in realizing simultaneous marketing approvals for pharmaceuticals within the European Community.
• To propose a cautious approach to regulatory reform, focusing on incremental improvements to existing procedures.
• To ensure the European pharmaceutical market maintains its competitive advantage and avoids drug lag.

Main Methods:

• Review of current European Community (EC) pharmaceutical regulatory procedures.
• Analysis of the implications of the single market concept for drug registration.
• Comparative assessment of potential benefits and risks associated with regulatory reform.

Main Results:

• The current regulatory framework hinders timely and simultaneous marketing approvals across EC member states.
• Abandoning established procedures for a new system introduces significant uncertainty and potential risks.
• Incremental improvements to existing processes offer a more viable path toward successful market integration.

Conclusions:

• Phased improvements to existing pharmaceutical regulatory systems are recommended over a complete overhaul.
• Failure to adapt regulatory procedures risks a "drug lag" and loss of competitive edge for Europe.
• Successful implementation of regulatory harmonization within the EC can serve as a model for global drug regulation efforts.